What We Do

Mr. Banjak joins iBio with over 15 years’ experience in the biotechnology and contract research industries. He previously served as the first general counsel of both Istari Oncology and Dova Pharmaceuticals, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through a number of clinical and corporate milestones, including FDA and EMA approvals, a secondary public offering and the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak negotiated strategic contracts, advised on Foreign Corrupt Practices Act (FCPA) and Anti-Bribery matters, and labor issues at PRA Health Sciences. His industry experience spans rare disease biotechnology companies, global contract research organizations, and medical device companies.  Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak was admitted to the Colorado state bar. He earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.

Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology^® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team’s research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.

Mr. Lutz brings more than 25 years of experience to iBio, joining most recently from Strongbridge Biopharma plc, a Nasdaq-listed, commercial-stage biopharmaceutical company focused on rare diseases. He served as Strongbridge’s CFO since August 2019, and prior to that, as its Chief Business Officer since October 2014. During his tenure, he led the search, evaluation, contracting, and financing of multiple assets which proved to be critical growth drivers for Strongbridge. Previously, Mr. Lutz spent more than a decade at Shire Pharmaceuticals in leadership positions with global responsibilities, including identifying opportunities for acquisition, licensing, partnership and development for Shire’s largest business unit (Neuroscience) and the financial management of approximately $5 billion in revenue for its Specialty Pharmaceuticals division. Prior to joining Shire, Mr. Lutz served in a variety of financial, strategic and executive positions after having started his career at Goldman Sachs & Company. He holds an MBA from the Kellogg School of Management and a BA in Economics and Computer Science from Amherst College.

Ms. Middlebrook is a human resources executive with a strong record of accomplishment for achieving results within the CDMO and Generics arenas. Most recently, she served as Senior Vice President, Human Resources-The Americas at Lupin Incorporated, a global pharmaceutical company offering branded and generic formulations, biosimilars and active pharmaceutical ingredients. Previously, Ms. Middlebrook’s more than 13 years of progressive experience at Lonza Group included executive roles as Global Head of Human Resources (Lonza Bioscience), Global Head of Leadership Development and Talent Management (Lonza AG), Head Integration (Lonza Inc.), Head of Human Resources & Environmental Health and Safety (Lonza Bioscience), in addition to earlier positions in staffing, human resources and employee relations. She holds an MS in Organizational Development from Johns Hopkins University and a BS in Industrial Relations from LeMoyne College.

Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business development and relationship management experience. Before joining iBio in December 2020, he was SVP and Chief Manufacturing Officer at Aptevo Therapeutics. Previously, Mr. Maddux was VP and Site Director at GlaxoSmithKline, where he led the largest biopharmaceutical development and manufacturing site within the GSK manufacturing network and was instrumental in launching a successful contract development and manufacturing (CDMO) services business. Prior to GSK, he was VP Quality and Operations at Human Genome Sciences and held positions of increasing responsibility within Biogen’s Quality organization. During his career, Mr. Maddux has served in key roles supporting the licensure and commercial launch of several biopharmaceutical products. He holds an MBA in Operations and Statistics from Duke University, Fuqua School of Business and a BS Professional in Analytical Chemistry from East Carolina University.

Dr. Melissa Berquist brings nearly 15 years of livestock infectious disease experience to the role of head of animal health programs. During her professional career, Dr. Berquist has directed two national Science and Technology Centers of Excellence and a World Organisation for Animal Health Collaborating Centre in biological threat reduction. She has contributed to White House- level policy documents related to the development and implementation of national-scale biosecurity and biosurveillance activities and has operationalized technology products into use by customers. Dr. Berquist has a strong understanding of animal health industry drivers, markets, and trends to be able to identify unmet needs and deliver solutions for relevant stakeholders. Prior to joining iBio, Dr. Berquist served as director for the Institute for Infectious Animal Diseases (IIAD) within the Texas A&M University System, where she oversaw executive operations, provided scientific leadership, and synchronized the unit’s efforts related to strategic management, organizational change, and efficiency. Dr. Berquist also served as the IIAD’s associate director for six years, prior to taking over the director role in 2017. She joined the Texas A&M University System following three years at BAI, Inc., a professional services company in Alexandria, Va., first as a senior biosurety analyst and then as a senior analyst and program coordinator supporting scientific activities and programmatic implementation of national-level biodefense portfolios. With diverse experience in delivering impactful tools and products to stakeholders and customers across the animal agricultural enterprise, she serves as a state-, national-, and global-level expert for a variety of animal health organizations. Dr. Berquist graduated from Northwestern University with a Bachelor of Science in biomedical engineering and earned her doctorate in molecular medicine/molecular and cellular biology as a Summa cum Laude graduate from the University of Maryland’s School of Medicine.

Dr. DeLong has more than a decade of business development, corporate development, and corporate strategy experience and has guided dozens of companies through transformative deals and challenging strategic decisions. Most recently, he served as head of business development for Tris Pharma, a commercial-stage specialty pharmaceutical company, where he led multiple transactions and mission-critical strategic initiatives related to the company's commercial drug portfolio and novel drug delivery platform technology. Prior to Tris, he spent 7 years at Locust Walk, a life sciences-focused transaction advisor and investment bank. During his time at Locust Walk, he worked on deal teams for over 40 transaction processes and strategy advising projects and executed multiple transformative deals for small and large companies. Earlier in his career, he co-founded Evolved Capital, a software as a service company providing return-on-investment analytics services to venture capital investors. He holds a PhD in Neuroscience from the University of Pennsylvania and a BA in Molecular Biology and Biochemistry from Rutgers University.

Dr. Greving has a record of innovation with more than 15 years of R&D experience. He is driven by a passion to integrate computation and laboratory technologies to improve biological discovery efficiency. Most recently, Dr. Greving served as Co-Founder and CTO at RubrYc Therapeutics where he led development of an AI-backed antibody discovery engine that generated a pre-clinical pipeline of epitope-selective antibodies. Previously, Dr. Greving served as Principal Scientist at HealthTell where he developed multiplexed computational-laboratory technologies to analyze antibody repertoires from blood for diagnostics. Prior to HealthTell, Dr. Greving was Co-Founder and CSO at Nextval that developed a high-throughput mass spectrometry and computational screening technology to measure drug toxicity at scale and to identify high activity enzyme variants from libraries. This resulted in two prestigious innovation awards: SLAS 2012 “Innovation of the Year”, and R&D Magazine’s 2013 “Oscar of Innovation”. Prior to graduate school, Dr. Greving spent 7 years as a Software Engineer developing high-throughput computing applications. Dr. Greving earned a Ph.D. in Biochemistry at Arizona State University and completed his post-doctoral research at Scripps Research.

Dr. Jenkins has three decades of experience in operations, business development and consulting. Before joining iBio, he was Senior Vice President CMC at Ridgeback Therapeutics during BLA preparation and eventual approval of ansuvimab. Prior to Ridgeback, Dr. Jenkins worked as a Senior Consultant at Bioprocessing Technology Consultants where he managed CDMO clients in both cell and gene therapy. He’s held technical and business roles in the mammalian cell culture space, helping to establish Catalent’s GPEx technology for mammalian cell line engineering and serving as the General Manager during construction of Catalent’s cGMP manufacturing site in Madison Wisconsin. Additionally, Dr. Jenkins held positions with increasing responsibility at CropTech Corporation, a company with a novel, inducible system to produce recombinant proteins in tobacco plants. Dr. Jenkins has a BS in Microbiology from the University of Illinois and a PhD in Molecular and Cellular Biology from the University of Arizona, where he studied the molecular genetics of UV sensitivity in plants.            

Mr. Luter brings over 25 years of experience in the field of information technology. Before joining iBio, he served as Sr. Director, Information Technology - The Americas at Lupin Incorporated, a global pharmaceutical company. During his tenure as Sr. Director, he aligned IT functions across the Brazil, Mexico, U.S., and Canada regions and successfully deployed advanced security and threat mitigation tools across all four regions. His 11 years of progressive experience at Lupin saw him build the U.S. information technology enterprise from the ground up, serving in roles as Director – IT Infrastructure & Support, Sr. Manager – IT Infrastructure & Support, and Manager – Information Technology. Previously, Mr. Luter spent 14 years in engineering and other information technology related roles in the television, news media, and server hosting industries. He holds a BBA in Business Information Systems from Mississippi State University.

Dr. Phan is an accomplished Drug Discovery leader with more than 15 years of industry experience in building and leading research teams to discover and develop therapeutic agents in diverse areas of unmet medical need. Most recently, Dr. Phan served as the director of In Vivo Pharmacology at Ferring Pharmaceuticals where he and his team conducted preclinical research to support Ferring’s global pipeline.  Previously, he held a position as Associate Director of Drug Discovery at Pfenex where he established the preclinical drug discovery infrastructure and co-developed an innovative rare disease and oncology strategy.  Prior to Pfenex, he was a Senior Investigator at The Genomics Institute of the Novartis Research Foundation where he led drug discovery programs in Type 1 Diabetes and Heart Failure indications. Dr. Phan spent 10 years at Gilead Sciences in the Cardiovascular Therapeutic Area after his postdoctoral fellow training at the University of Texas, Southwestern Medical Center.  During his tenure at Gilead Sciences as Senior Research Scientist, Dr. Phan and his team identified and validated numerous targets, initiated drug discovery programs and co-led a novel kinase inhibitor program into the clinic for Diabetic Kidney Disease and Pulmonary Arterial Hypertension. Dr. Phan earned his Ph.D. at the University of Texas, MD Anderson Cancer Center in Molecular Pathology and his B.S in Genetics from the University of California at Davis.